Dissemin is shutting down on January 1st, 2025

Published in

Springer Nature [academic journals on nature.com], Bone Marrow Transplantation, 7(48), p. 908-914, 2013

DOI: 10.1038/bmt.2013.66

Springer Nature [academic journals on nature.com], Bone Marrow Transplantation, 12(48), p. 1588-1588, 2013

DOI: 10.1038/bmt.2013.183

Links

Tools

Export citation

Search in Google Scholar

In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study

This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Orange circle
Postprint: archiving restricted
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

The aim of this study was to determine whether parameters related to TBI impacted upon OS and relapse in patients with acute leukemia in CR who underwent haematopoietic SCT (HSCT) in 11 Italian Radiation Oncology Centres. Data were analysed from 507 patients (313 males; 194 females; median age 15 years; 318 with ALL; 188 with AML; 1 case not recorded). Besides 128 autologous transplants, donors included 192 matched siblings, 74 mismatched family members and 113 unrelated individuals. Autologous and allogeneic transplants were analysed separately. Median follow-up was 40.1 months. TBI schedules and HSCT type were closely related. Uni- and multi-variate analyses showed no parameter was significant for OS or relapse in autologous transplantation. Multivariate analysis showed type of transplant and disease impacted significantly on OS in allogeneic transplantation. Disease, GVHD and TBI dose were risk factors for relapse. This analysis illustrates that Italian Transplant Centre use of TBI is in line with international practice. Most Centres adopted a hyperfractionated schedule that is used worldwide (12 Gy in six fractions over 3 days), which appears to have become standard. TBI doses impacted significantly upon relapse rates.Bone Marrow Transplantation advance online publication, 27 May 2013; doi:10.1038/bmt.2013.66.